Market Cap
PE TTM
Negative PE TTM
PEG TTM
Price to Book
Low in industry
Beta 1Year
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Scott P. Bruder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,607 | 14,607 | - | - | Stock Options (Right to Buy) | |
| Naseem Amin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 47,578 | 291,865 (0%) | 0% | 0 | Common Stock | |
| Martin Dekker | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 50,000 | 50,000 | - | - | Stock Options (Right to Buy) | |
| Peter Fernandes | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 100,000 | 100,000 | - | - | Stock Options (Right to Buy) | |
| Mary Ann Cloyd | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,607 | 14,607 | - | - | Stock Options (Right to Buy) | |
| Parag Shah | VP of Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 50,000 | 50,000 | - | - | Stock Options (Right to Buy) | |
| Crispin Teufel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,607 | 14,607 | - | - | Stock Options (Right to Buy) | |
| Bobae Kim | VP Reg. Affairs & Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 50,000 | 50,000 | - | - | Stock Options (Right to Buy) | |
| Bobae Kim | VP Reg. Affairs & Quality | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 266 | 0 | - | - | Stock Options (Right to Buy) | |
| Bobae Kim | VP Reg. Affairs & Quality | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 18 May 2023 | 9,455 | 1,723 (0%) | 0% | 10 | 94,550 | Common Stock |
| Bobae Kim | VP Reg. Affairs & Quality | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.50 per share. | 18 May 2023 | 1,022 | 1,723 (0%) | 0% | 7.5 | 7,665 | Common Stock |
| Bobae Kim | VP Reg. Affairs & Quality | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.35 per share. | 18 May 2023 | 266 | 1,723 (0%) | 0% | 7.3 | 1,955 | Common Stock |
| Bobae Kim | VP Reg. Affairs & Quality | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 1,022 | 144 | - | - | Stock Options (Right to Buy) | |
| Scott P. Bruder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 29,000 | 29,000 | - | - | Stock Options (right to buy) | |
| Naseem Amin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 84,000 | 244,287 (0%) | 0% | 0 | Common Stock | |
| Martin Dekker | VP OF ENGINEERING & MANUFACTUR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 50,000 | 50,000 | - | - | Stock Options (right to buy) | |
| Peter Fernandes | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 100,000 | 100,000 | - | - | Stock Options (right to buy) | |
| Mary Ann Cloyd | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 29,000 | 29,000 | - | - | Stock Options (right to buy) | |
| Parag Shah | VP OF BUSINESS OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 50,000 | 50,000 | - | - | Stock Options (right to buy) | |
| Theodore T. Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 29,000 | 29,000 | - | - | Stock Options (right to buy) | |
| Crispin Teufel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 29,000 | 29,000 | - | - | Stock Options (right to buy) | |
| Nicholas Laccona | FINANCIAL OFFICER, (PFO & PAO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 50,000 | 50,000 | - | - | Stock Options (right to buy) | |
| Martin Dekker | VP OF ENGINEERING & MANUFACTUR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 25,500 | 25,500 (0%) | 0% | - | Common Stock | |
| Martin Dekker | VP OF ENGINEERING & MANUFACTUR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 25,500 | 25,500 | - | - | Restricted Stock Units | |
| Martin Dekker | VP OF ENGINEERING & MANUFACTUR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.93 per share. | 09 Dec 2022 | 7,834 | 17,666 (0%) | 0% | 0.9 | 7,286 | Common Stock |
| Peter Fernandes | PRINCIPAL EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 32,500 | 32,500 | - | - | Restricted Stock Units | |
| Peter Fernandes | PRINCIPAL EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 32,500 | 32,500 (0%) | 0% | - | Common Stock | |
| Peter Fernandes | PRINCIPAL EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.93 per share. | 09 Dec 2022 | 9,985 | 22,515 (0%) | 0% | 0.9 | 9,287 | Common Stock |
| Parag Shah | VP OF BUSINESS OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 25,500 | 25,500 | - | - | Restricted Stock Units | |
| Parag Shah | VP OF BUSINESS OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 25,500 | 25,500 (0%) | 0% | - | Common Stock | |
| Parag Shah | VP OF BUSINESS OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.93 per share. | 09 Dec 2022 | 7,834 | 17,666 (0%) | 0% | 0.9 | 7,286 | Common Stock |
| Nicholas Laccona | FINANCIAL OFFICER, (PFO & PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 18,000 | 18,000 | - | - | Restricted Stock Units | |
| Nicholas Laccona | FINANCIAL OFFICER, (PFO & PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 18,000 | 18,000 (0%) | 0% | - | Common Stock | |
| Nicholas Laccona | FINANCIAL OFFICER, (PFO & PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.93 per share. | 09 Dec 2022 | 5,530 | 12,470 (0%) | 0% | 0.9 | 5,143 | Common Stock |
| Martin Dekker | VP OF ENGINEERING & MANUFACTUR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 51,000 | 51,000 | - | - | Restricted Stock Units | |
| Peter Fernandes | CHIEF REGULATORY & SAFETY OFFR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 65,000 | 65,000 | - | - | Restricted Stock Units | |
| Parag Shah | VP OF BUSINESS OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 51,000 | 51,000 | - | - | Restricted Stock Units | |
| Nicholas Laccona | FINANCIAL OFFICER, (PFO & PAO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 36,000 | 36,000 | - | - | Restricted Stock Units | |
| Jonathan M. Peacock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 15,308 | 157,033 (0%) | 0% | 0 | Common Stock | |
| Scott P. Bruder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 6,509 | 15,138 | - | - | Stock Option (right to buy) | |
| Matthew M. Bennett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 6,509 | 6,509 | - | - | Stock Option (right to buy) | |
| Naseem Amin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 6,509 | 15,138 | - | - | Stock Option (right to buy) | |
| Andre V. Moura | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 6,509 | 13,472 | - | - | Stock Option (right to buy) | |
| Mary Ann Cloyd | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 6,509 | 14,472 | - | - | Stock Option (right to buy) | |
| Theodore Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 6,509 | 13,806 | - | - | Stock Option (right to buy) | |
| Crispin Teufel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 6,509 | 11,259 | - | - | Stock Option (right to buy) | |
| Wassim Fares | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 10.18 per share. | 10 Sep 2020 | 4,000 | 4,000 (0%) | 0% | 10.2 | 40,708 | Common Stock |
| Wassim Fares | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 12.87 per share. | 05 Jun 2020 | 2,600 | 60,913 (0%) | 0% | 12.9 | 33,454 | Common Stock |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 12.72 per share. | 05 Jun 2020 | 4,986 | 58,313 (0%) | 0% | 12.7 | 63,442 | Common Stock |
| Jonathan M. Peacock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 350,000 | 2,225,920 (3%) | 0% | 0 | Common Stock | |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.39 per share. | 21 Nov 2019 | 7,193 | 592,922 (0%) | 0% | 0.4 | 2,774 | Common Stock |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.38 per share. | 21 Nov 2019 | 1,050 | 585,729 (0%) | 0% | 0.4 | 394 | Common Stock |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 21 Nov 2019 | 200 | 584,679 (0%) | 0% | 0.4 | 74 | Common Stock |
| Fabian Tenenbaum | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 15 Nov 2019 | 76,823 | 407,459 (0%) | 0% | 0.3 | 26,120 | Common Stock |
| Martin Dekker | VP of Engineering & Manuf | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 15 Nov 2019 | 27,134 | 124,619 (0%) | 0% | 0.3 | 9,226 | Common Stock |
| Peter Fernandes | Chief Regulatory & Safety Offr | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 15 Nov 2019 | 40,280 | 182,022 (0%) | 0% | 0.3 | 13,695 | Common Stock |
| Parag Shah | VP of Business Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 15 Nov 2019 | 25,993 | 105,606 (0%) | 0% | 0.3 | 8,838 | Common Stock |
| Assaf Korner | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 15 Nov 2019 | 32,987 | 66,078 (0%) | 0% | 0.3 | 11,216 | Common Stock |
| Scott P. Bruder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 46,266 | 129,482 | - | - | Stock Option (right to buy) | |
| Matthew M. Bennett | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 46,266 | 84,482 | - | - | Stock Option (right to buy) | |
| Fabian Tenenbaum | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 1,752,000 | 5,440,697 | - | - | Stock Option (right to buy) | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 46,266 | 109,482 | - | - | Stock Option (right to buy) | |
| Martin Dekker | VP of Engineering & Manuf | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 175,500 | 438,483 | - | - | Stock Option (right to buy) | |
| Andre V. Moura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 46,266 | 104,482 | - | - | Stock Option (right to buy) | |
| Peter Fernandes | Chief Regulatory & Safety Offr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 175,500 | 470,290 | - | - | Stock Option (right to buy) | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 175,500 | 445,886 | - | - | Stock Option (right to buy) | |
| Mary Ann Cloyd | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 46,266 | 119,482 | - | - | Stock Option (right to buy) | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 175,500 | 445,854 | - | - | Stock Option (right to buy) | |
| Theodore Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 46,266 | 109,482 | - | - | Stock Option (right to buy) | |
| Assaf Korner | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 175,500 | 425,500 | - | - | Stock Option (right to buy) | |
| Crispin Teufel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2019 | 46,266 | 71,266 | - | - | Stock Option (right to buy) | |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 12 Jun 2019 | 50,000 | 584,479 (0%) | 0% | 0.6 | 31,905 | Common Stock |
| Crispin Teufel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Amy Edmonds | VP Clinical Operations & Admin | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.61 per share. | 22 May 2019 | 35,827 | 140,216 (0%) | 0% | 0.6 | 21,797 | Common Stock |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.60 per share. | 22 May 2019 | 27,500 | 534,479 (0%) | 0% | 0.6 | 16,533 | Common Stock |
| Fabian Tenenbaum | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.60 per share. | 21 May 2019 | 5,000 | 484,282 (0%) | 0% | 0.6 | 2,975 | Common Stock |
| Jonathan M. Peacock | None | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 21 May 2019 | 20,000 | 1,875,920 (2%) | 0% | 0.6 | 12,198 | Common Stock |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 21 May 2019 | 43,280 | 506,979 (0%) | 0% | 0.6 | 26,371 | Common Stock |
| Naseem Amin | None | Purchase of securities on an exchange or from another person at price $ 0.70 per share. | 25 Jan 2019 | 571,429 | 1,818,867 (2%) | 0% | 0.7 | 400,000 | Common Stock |
| Jonathan M. Peacock | None | Purchase of securities on an exchange or from another person at price $ 0.70 per share. | 25 Jan 2019 | 714,286 | 1,855,920 (2%) | 1% | 0.7 | 500,000 | Common Stock |
| Theodore Wang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.70 per share. | 25 Jan 2019 | 450,000 | 463,699 (0%) | 0% | 0.7 | 315,000 | Common Stock |
| Jonathan M. Peacock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2019 | 227,273 | 1,141,634 (1%) | 0% | 0 | Common Stock | |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 12,500 | 3,688,697 | - | - | Stock Option (right to buy) | |
| Martin Dekker | VP of Engineering & Manuf | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 12,500 | 262,983 | - | - | Stock Option (right to buy) | |
| Peter Fernandes | Chief Regulatory & Safety Offr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 12,500 | 294,790 | - | - | Stock Option (right to buy) | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 12,500 | 270,386 | - | - | Stock Option (right to buy) | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 12,500 | 260,000 | - | - | Stock Option (right to buy) | |
| Assaf Korner | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 12,500 | 250,000 | - | - | Stock Option (right to buy) | |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2018 | 1,487,500 | 3,676,197 | - | - | Stock Option (right to buy) | |
| Martin Dekker | VP of Engineering & Manuf | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2018 | 137,500 | 250,483 | - | - | Stock Option (right to buy) | |
| Peter Fernandes | Chief Regulatory & Safety Offr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2018 | 137,500 | 282,290 | - | - | Stock Option (right to buy) | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2018 | 137,500 | 257,886 | - | - | Stock Option (right to buy) | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2018 | 137,500 | 247,500 | - | - | Stock Option (right to buy) | |
| Assaf Korner | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2018 | 137,500 | 237,500 | - | - | Stock Option (right to buy) | |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2018 | 224,299 | 479,282 (0%) | 0% | 0 | Common Stock | |
| Martin Dekker | VP of Engineering & Manuf | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2018 | 82,243 | 151,753 (0%) | 0% | 0 | Common Stock | |
| Peter Fernandes | Chief Regulatory & Safety Offr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2018 | 119,626 | 222,302 (0%) | 0% | 0 | Common Stock | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2018 | 82,243 | 176,043 (0%) | 0% | 0 | Common Stock | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2018 | 78,505 | 131,599 (0%) | 0% | 0 | Common Stock | |
| Assaf Korner | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2018 | 99,065 | 99,065 (0%) | 0% | 0 | Common Stock | |
| Matthew M. Bennett | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2018 | 11,987 | 30,552 (0%) | 0% | 0 | Common Stock | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2018 | 17,124 | 1,247,438 (2%) | 0% | 0 | Common Stock | |
| Jens Luehring | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2018 | 14,555 | 95,213 (0%) | 0% | 0 | Common Stock | |
| Daniel Tasse | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2018 | 11,987 | 182,604 (0%) | 0% | 0 | Common Stock | |
| Andre V. Moura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2018 | 15,411 | 68,736 (0%) | 0% | 0 | Common Stock | |
| Theodore Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2018 | 13,699 | 13,699 (0%) | 0% | 0 | Common Stock | |
| Fabian Tenenbaum | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 12 Jun 2018 | 63,486 | 254,983 (0%) | 0% | 2.4 | 150,462 | Common Stock |
| Deborah A. Quinn | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 12 Jun 2018 | 10,541 | 94,070 (0%) | 0% | 2.4 | 24,982 | Common Stock |
| Martin Dekker | VP of Engineering & Manuf | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 12 Jun 2018 | 7,473 | 69,510 (0%) | 0% | 2.4 | 17,711 | Common Stock |
| Peter Fernandes | Chief Regulatory & Safety Offr | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 12 Jun 2018 | 11,304 | 102,676 (0%) | 0% | 2.4 | 26,790 | Common Stock |
| Amy Edmonds | VP Clinical Operations & Admin | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 12 Jun 2018 | 7,499 | 93,800 (0%) | 0% | 2.4 | 17,773 | Common Stock |
| Parag Shah | VP Proj Mgmt & Distribution | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 12 Jun 2018 | 7,144 | 53,094 (0%) | 0% | 2.4 | 16,931 | Common Stock |
| Scott P. Bruder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 83,216 | - | - | Stock Option (right to buy) | |
| Matthew M. Bennett | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 38,216 | - | - | Stock Option (right to buy) | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 83,216 | - | - | Stock Option (right to buy) | |
| Jens Luehring | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 58,216 | - | - | Stock Option (right to buy) | |
| Daniel Tasse | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 58,216 | - | - | Stock Option (right to buy) | |
| Andre V. Moura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 58,216 | - | - | Stock Option (right to buy) | |
| Maryann Cloyd | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 73,216 | - | - | Stock Option (right to buy) | |
| Theodore Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 38,216 | 63,216 | - | - | Stock Option (right to buy) | |
| Jonathan M. Peacock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 99,010 | 914,361 (1%) | 0% | 0 | Common Stock | |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 550,000 | 550,000 | - | - | Stock Option (right to buy) | |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 55,419 | 318,469 (0%) | 0% | 0 | Common Stock | |
| Deborah A. Quinn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Deborah A. Quinn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 29,557 | 104,611 (0%) | 0% | 0 | Common Stock | |
| Martin Dekker | VP of Engineering & Manuf | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 21,675 | 76,983 (0%) | 0% | 0 | Common Stock | |
| Martin Dekker | VP of Engineering & Manuf | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Peter Fernandes | Chief Regulatory & Safety Offr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 31,527 | 113,980 (0%) | 0% | 0 | Common Stock | |
| Peter Fernandes | Chief Regulatory & Safety Offr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 21,675 | 101,299 (0%) | 0% | 0 | Common Stock | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 20,690 | 60,238 (0%) | 0% | 0 | Common Stock | |
| Assaf Korner | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Deborah A. Quinn | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.49 per share. | 04 Jan 2018 | 33,114 | 75,054 (0%) | 0% | 2.5 | 82,454 | Common Stock |
| Martin Dekker | VP of Engineering & Manuf | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.49 per share. | 04 Jan 2018 | 24,284 | 55,308 (0%) | 0% | 2.5 | 60,467 | Common Stock |
| Peter Fernandes | Chief Regulatory & Safety Offr | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.49 per share. | 04 Jan 2018 | 35,321 | 82,453 (0%) | 0% | 2.5 | 87,949 | Common Stock |
| Parag Shah | VP Proj Mgmt & Distribution | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.49 per share. | 04 Jan 2018 | 23,180 | 39,548 (0%) | 0% | 2.5 | 57,718 | Common Stock |
| Megan Schoeps | Principal Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2017 | 1,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Megan Schoeps | Principal Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 13 Dec 2017 | 1,000 | 19,248 (0%) | 0% | 0.5 | 490 | Common Stock |
| Theodore Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2017 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Naseem Amin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Sep 2017 | 456,432 | 456,432 | - | - | Common Stock Warrants (right to buy) | |
| Naseem Amin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Sep 2017 | 456,432 | 1,230,314 (2%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Sep 2017 | 248,962 | 815,351 (1%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Sep 2017 | 248,962 | 248,962 | - | - | Common Stock Warrants (right to buy) | |
| Jens Luehring | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Sep 2017 | 10,000 | 80,658 (0%) | 0% | 0 | Common Stock | |
| Jens Luehring | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Sep 2017 | 10,000 | 10,000 | - | - | Common Stock Warrants (right to buy) | |
| Scott P. Bruder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Jonathan M. Peacock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Adam B. Weinstein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Jens Luehring | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Daniel Tasse | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Andre V. Moura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Maryann Cloyd | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2017 | 36,232 | 773,882 (2%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2017 | 57,972 | 566,389 (1%) | 0% | 0 | Common Stock | |
| Adam B. Weinstein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2017 | 25,363 | 42,130 (0%) | 0% | 0 | Common Stock | |
| Jens Luehring | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2017 | 30,798 | 70,658 (0%) | 0% | 0 | Common Stock | |
| Daniel Tasse | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2017 | 25,363 | 170,617 (0%) | 0% | 0 | Common Stock | |
| Andre V. Moura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2017 | 32,609 | 53,325 (0%) | 0% | 0 | Common Stock | |
| Megan Schoeps | Principal Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.40 per share. | 17 May 2017 | 10,459 | 18,248 (0%) | 0% | 1.4 | 14,683 | Common Stock |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2017 | 120,193 | 263,050 (0%) | 0% | 0 | Common Stock | |
| Deborah A. Quinn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2017 | 76,924 | 108,168 (0%) | 0% | 0 | Common Stock | |
| Martin Dekker | VP of Engineering & Manuf | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2017 | 56,411 | 79,592 (0%) | 0% | 0 | Common Stock | |
| Peter Fernandes | Chief Regulatory & Safety Offr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2017 | 82,052 | 117,774 (0%) | 0% | 0 | Common Stock | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2017 | 56,411 | 79,624 (0%) | 0% | 0 | Common Stock | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2017 | 53,847 | 62,728 (0%) | 0% | 0 | Common Stock | |
| Megan Schoeps | Principal Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2017 | 24,039 | 28,707 (0%) | 0% | 0 | Common Stock | |
| Jens Luehring | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 09 Dec 2016 | 20,000 | 39,860 | - | - | Common Stock | |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2016 | 1,042,556 | 1,042,556 | - | - | Stock Option (right to buy) | |
| Jonathan M. Peacock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2016 | 588,373 | 588,373 | - | - | Stock Option (right to buy) | |
| Deborah A. Quinn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2016 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Martin Dekker | VP of Device Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2016 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Peter Fernandes | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2016 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2016 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Parag Shah | VP Proj Mgmt & Distribution | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2016 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Fabian Tenenbaum | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Nov 2016 | 142,857 | 142,857 | - | - | Common Stock Warrants (right to buy) | |
| Fabian Tenenbaum | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Nov 2016 | 142,857 | 142,857 | - | - | Common Stock | |
| Naseem Amin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Nov 2016 | 714,285 | 714,285 | - | - | Common Stock Warrants (right to buy) | |
| Naseem Amin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Nov 2016 | 714,285 | 737,650 | - | - | Common Stock | |
| Jonathan M. Peacock | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Nov 2016 | 285,715 | 285,715 | - | - | Common Stock Warrants (right to buy) | |
| Jonathan M. Peacock | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Nov 2016 | 285,715 | 508,417 | - | - | Common Stock | |
| Fabian Tenenbaum | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2016 | 466,141 | 466,141 | - | - | Stock Option (right to buy) | |
| Deborah A. Quinn | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 12 Sep 2016 | 18,548 | 31,244 | - | - | Common Stock | |
| Martin Dekker | VP of Device Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 12 Sep 2016 | 13,333 | 23,181 | - | - | Common Stock | |
| Peter Fernandes | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 12 Sep 2016 | 19,785 | 35,722 | - | - | Common Stock | |
| Amy Edmonds | VP Clinical Operations & Admin | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 12 Sep 2016 | 13,301 | 23,213 | - | - | Common Stock | |
| Parag Shah | VP Proj Mgmt & Distribution | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 12 Sep 2016 | 4,673 | 8,881 | - | - | Common Stock | |
| Scott P. Bruder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Adam B. Weinstein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Jens Luehring | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Daniel Tasse | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Matthew Holt | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Andre V. Moura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Jonathan M. Peacock | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 May 2016 | 5,000 | 222,702 | - | - | Common Stock | |
| Scott P. Bruder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 18,692 | 18,692 | - | - | Common Stock | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 23,365 | 23,365 | - | - | Common Stock | |
| Adam B. Weinstein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 16,767 | 16,767 | - | - | Common Stock | |
| Jens Luehring | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 19,860 | 19,860 | - | - | Common Stock | |
| Daniel Tasse | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 16,356 | 145,254 | - | - | Common Stock | |
| Matthew Holt | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 18,232 | 18,232 | - | - | Common Stock | |
| Andre V. Moura | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 20,716 | 20,716 | - | - | Common Stock | |
| Maryann Cloyd | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2016 | 21,858 | 21,858 | - | - | Common Stock | |
| Fabian Tenenbaum | CFO & Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2016 | 130,000 | 130,000 | - | - | Stock Option (right to buy) | |
| Maryann Cloyd | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2016 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Jonathan M. Peacock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 165,975 | 217,702 | - | - | Common Stock | |
| Deborah A. Quinn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2016 | 49,792 | 49,792 | - | - | Common Stock | |
| Martin Dekker | VP of Device Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2016 | 36,514 | 36,514 | - | - | Common Stock | |
| Peter Fernandes | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2016 | 53,112 | 55,507 | - | - | Common Stock | |
| Amy Edmonds | VP Clinical Operations & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2016 | 36,514 | 36,514 | - | - | Common Stock | |
| Jonathan M. Peacock | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Dec 2015 | 12,800 | 51,727 | - | - | Common Stock | |
| Jonathan M. Peacock | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Dec 2015 | 7,500 | 38,927 | - | - | Common Stock | |
| David M. Abrams | Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2015 | 13,116 | 13,116 | - | - | Common Stock | |
| Jonathan M. Peacock | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Aug 2015 | 5,000 | 31,427 | - | - | Common Stock | |
| Amit Agrawal | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2015 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Naseem Amin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2015 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Martin D. Meglasson | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 May 2015 | 712 | 19,098 | - | - | Common Stock | |
| Jonathan M. Peacock | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 May 2015 | 5,560 | 26,427 | - | - | Common Stock | |
| Peter Fernandes | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2015 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| R. Scott Huennekens | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2015 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Scott P. Bruder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2015 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Martin D. Meglasson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2015 | 8,297 | 8,297 | - | - | Stock Option (right to buy) | |
| Jonathan M. Peacock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2015 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Jonathan M. Peacock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2015 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| David M. Abrams | Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2015 | 2,564 | 2,564 | - | - | Stock Option (right to buy) | |
| Manesh Naidu | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2015 | 4,892 | 4,892 | - | - | Stock Option (right to buy) | |
| Reinilde Heyrman | Chief Clinical Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2015 | 9,909 | 9,909 | - | - | Stock Option (right to buy) | |
| Steven B. Klinsky | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 1,070,166 | 4,859,885 | - | - | Common Stock | |
| Keith L. Crandell | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 212,666 | 965,660 | - | - | Common Stock | |
| Martin D. Meglasson | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 12,000 | 18,386 | - | - | Common Stock | |
| Jonathan M. Peacock | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 20,800 | 20,867 | - | - | Common Stock | |
| Jens Luehring | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 358,916 | 1,629,804 | - | - | Common Stock | |
| Daniel Tasse | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 25,000 | 128,898 | - | - | Common Stock | |
| Manesh Naidu | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 1,500 | 11,319 | - | - | Common Stock | |
| Reinilde Heyrman | Chief Clinical Dev. Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 1,500 | 9,483 | - | - | Common Stock | |
| Martin D. Meglasson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2015 | 1,995 | 1,995 | - | - | Stock Option (right to buy) | |
| David M. Abrams | Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2015 | 1,995 | 1,995 | - | - | Stock Option (right to buy) | |
| Manesh Naidu | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2015 | 1,995 | 1,995 | - | - | Stock Option (right to buy) | |
| Reinilde Heyrman | Chief Clinical Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2015 | 1,995 | 1,995 | - | - | Stock Option (right to buy) | |
| Robert T. Nelsen | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Feb 2015 | 212,666 | 965,660 | - | - | Common Stock | |
| Robert T. Nelsen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2015 | 752,994 | 752,994 | - | - | Common Stock | |
| Robert T. Nelsen | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2015 | 752,994 | 0 | - | - | Common Stock | |
| Adam B. Weinstein | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2015 | 460,144 | 3,329,575 | - | - | Common Stock | |
| Adam B. Weinstein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2015 | 460,144 | 3,789,719 | - | - | Common Stock | |
| Adam B. Weinstein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Feb 2015 | 1,070,166 | 4,859,885 | - | - | Common Stock | |
| Matthew Holt | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Feb 2015 | 1,070,166 | 4,859,885 | - | - | Common Stock | |
| Matthew Holt | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2015 | 460,144 | 3,789,719 | - | - | Common Stock | |
| Matthew Holt | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2015 | 460,144 | 3,329,575 | - | - | Common Stock |